Key clinical papers

2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia BJ Haem 2025
https://onlinelibrary.wiley.com/doi/10.1111/bjh.70100 

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia NEJM 2025
https://www.nejm.org/doi/10.1056/NEJMoa2504341

A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial Lancet Haematology 2025
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00008-0/fulltext

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease NEJM 2023
https://www.nejm.org/doi/10.1056/NEJMoa2310063

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology 2023
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00144-4/fulltext

Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors. Am J Haem 2022
https://onlinelibrary.wiley.com/doi/10.1002/ajh.26483

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study J Clin Oncol 2019
https://ascopubs.org/doi/full/10.1200/JCO.19.00894

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia. Blood. 2022.
Commentary by Tatjana Stankovic and Marwan Kwok
Institute of Cancer and Genomic Sciences, University of Birmingham, UK